For the Inventor, By the Inventor

Enter assignee name

Zwijnaarde, Belgium

Intrexon Actobiotics N.v.

USPTO Granted Patents = 27

CIPO Patents = 5

EPO Patents = 19

Trademarks = 1

Forward Citations = 25

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Lothar Steidler (20 out of 28 patents)

Pieter Rottiers (11 out of 15 patents)

Klaas Vandenbroucke (10 out of 12 patents)

4. Karolien Van Huynegem (8 out of 8 patents)

5. Veerle Snoeck (5 out of 19 patents)

6. Sam Corveleyn (3 out of 3 patents)

7. Patrick Dhaese (3 out of 3 patents)

8. Sabine Neirynck (3 out of 4 patents)

9. Erik Remaut (2 out of 3 patents)

10. Dirk Iserentant (2 out of 4 patents)

11. Klaas Vanden-Broucke (1 out of 1 patent)

12. Sabine Neirynck (3 patents)

27 patents: Sort by Forward Citations

1. 12359210 - Genetically modified bacteria stably expressing IL-10 and insulin (2025-07-15),

2. 12252516 - Mucoadhesive microorganism (2025-03-18),

3. 12246046 - Compositions and methods for the treatment of type 1 diabetes (2025-03-11),

4. 11786567 - Compositions and methods for the treatment of type 1 diabetes (2023-10-17),

5. 11633438 - Cryoprotectants for freeze drying of lactic acid bacteria (2023-04-25),

6. 11549118 - Genetically modified bacteria stably expressing IL-10 and insulin (2023-01-10),

7. 11384123 - Mucoadhesive microorganism (2022-07-12),

8. 10988770 - Polycistronic expression system for bacteria (2021-04-27),

9. 10905727 - Compositions and methods for the treatment of type 1 diabetes (2021-02-02),

10. 10858663 - Genetically modified bacteria stably expressing IL-10 and insulin (2020-12-08),

11. 10808014 - Mucoadhesive microorganism (2020-10-20),

12. 10793825 - Modified gram positive bacteria and uses thereof (2020-10-06),

13. 10668136 - Treatment of immune disease by mucosal delivery of antigens using genetically modified (2020-06-02),

14. 10596207 - Cryoprotectants for freeze drying of lactic acid bacteria (2020-03-24),

15. 10519418 - Modified gram positive bacteria and uses thereof (2019-12-31),

INTREXON ACTOBIOTICS N.V. is a biotechnology company specializing in the development of novel therapeutics and biocontrol products. They leverage advanced synthetic biology techniques to engineer living bacteria, known as Actobiotics, to deliver targeted therapeutic payloads or act as biocontrol agents. Actobiotics have the ability to colonize specific areas of the body, providing a platform for the localized production and delivery of various therapeutic molecules. Through their innovative approach, INTREXON ACTOBIOTICS N.V. aims to revolutionize the treatment of various diseases and improve agricultural practices.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

27 Patents

#4 in Zwijnaarde

#124 in Belgium

#23,293 in the World

Zwijnaarde, Belgium

Intrexon Actobiotics N.v.

Forward Citations = 25

11 inventors:

Lothar Steidler (20 out of 28 patents)

Pieter Rottiers (11 out of 15 patents)

Klaas Vandenbroucke (10 out of 12 patents)

4. Karolien Van Huynegem (8 out of 8 patents)

5. Veerle Snoeck (5 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…